MeiraGTx Holdings plc Increase (Decrease) in Other Receivables
MeiraGTx Holdings plc (MGTX) reported Increase (Decrease) in Other Receivables of -$437.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherReceivables · last filed 2026-08-13
- MeiraGTx Holdings plc increase (decrease) in other receivables for the quarter ending 2025-12-31 was $6.08M, a 47.73% increase year-over-year.
- MeiraGTx Holdings plc increase (decrease) in other receivables for the quarter ending 2025-09-30 was $4.69M, a 231.07% increase year-over-year.
- MeiraGTx Holdings plc increase (decrease) in other receivables for the quarter ending 2025-06-30 was $0.00.
- MeiraGTx Holdings plc increase (decrease) in other receivables for the quarter ending 2025-03-31 was -$4.85M.
- MeiraGTx Holdings plc increase (decrease) in other receivables for fiscal 2025 was $5.92M.
- MeiraGTx Holdings plc increase (decrease) in other receivables for fiscal 2024 was -$4.05M, a 178.77% decline from fiscal 2023.
- MeiraGTx Holdings plc increase (decrease) in other receivables for fiscal 2023 was $5.15M.
- MeiraGTx Holdings plc increase (decrease) in other receivables for fiscal 2022 was -$4.14M.
| Period end | Increase (Decrease) in Other Receivables 3 month | Increase (Decrease) in Other Receivables 6 month | Increase (Decrease) in Other Receivables 9 month | Increase (Decrease) in Other Receivables 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$437.00K 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $6.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $10.77M derived: sum of 2 quarters · filed 2026-03-30 | $10.77M derived: sum of 3 quarters · filed 2026-08-13 | $5.92M 10-K · filed 2026-03-30 |
| 2025-09-30 | $4.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $4.69M derived: sum of 2 quarters · filed 2026-08-13 | -$163.00K 10-Q · filed 2025-11-13 | $3.95M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$4.85M 10-Q · filed 2026-08-13 | -$736.00K derived: sum of 3 quarters · filed 2026-08-13 | $680.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$4.85M 10-Q · filed 2026-05-14 | -$736.00K derived: sum of 2 quarters · filed 2026-05-14 | $680.00K derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | $4.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $5.53M derived: sum of 2 quarters · filed 2026-03-30 | -$4.05M 10-K · filed 2026-03-30 | |
| 2024-09-30 | $1.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$8.17M 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | -$9.59M 10-Q · filed 2025-08-14 | |||
| 2023-12-31 | $2.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $5.15M 10-K · filed 2025-03-13 | ||
| 2023-09-30 | $2.28M 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | $2.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$4.14M 10-K · filed 2024-03-15 | ||
| 2022-09-30 | -$6.52M 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |